Alvotech stated that it designed the study to evaluate the safety, tolerability, and immunogenicity profiles of AVT80 and ...

REYKJAVIK, Iceland, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotechnology company specializing in ...

This is the third program that successfully combines Entera’s oral peptide N-Tab® platform with OPKO’s advanced protein chemistry capabilitiesThe ...

PF'3944 is an ultra-long-acting fully biased GLP-1 receptor agonist (RA). It is being developed as a single agent weekly and as a monthly therapy, and in combination with various peptides including an ...

The US Food and Drug Administration rejected a subcutaneous version of AstraZeneca Plc’s lupus medicine that would make it easier to administer.

The company is working with the U.S. regulator to move forward with an updated application, adding a decision is expected in ...

Halozyme (HALO) outlook: acquisitions extend IP beyond 2027, royalties are set to top $1B in 2026, and shares look discounted ...

The FDA is reviewing an application seeking expanded approval of an under-the-skin injection version of Leqembi (lecanemab).

Subcutaneous Saphnelo may offer people with lupus more convenient dosing with efficacy similar to the approved infusion version of the therapy, data show.

Monash University researchers, alongside key partner Halozyme Therapeutics, report findings in support of shifting the way ...

Previously lecanemab was only approved as an SC injection for maintenance dosing, following an initial 18 month IV phase.

Mounjaro (tirzepatide) is prescribed to manage blood sugar levels in people with type 2 diabetes. It’s available as a single-dose prefilled pen. You will administer your Mounjaro injections into your ...